Novartis to Establish Radioligand Therapy Manufacturing Facility in Texas: Enhancing U.S. Manufacturing Capabilities for Targeted Cancer Treatments
Novartis has announced plans to establish a radioligand therapy manufacturing facility in Texas, marking its first such site in the state and fifth in the United States. This investment is part of the company's $23 billion initiative to enhance its U.S. manufacturing capabilities in response to the Trump administration's tariffs on pharmaceutical imports. The new facility will support the production of targeted cancer treatments that deliver radiation directly to tumor cells, complementing Novartis' existing portfolio of radioligand drugs.
Novartis CEO Vas Narasimhan emphasized the importance of expanding manufacturing capacity to meet the growing demand for next-generation treatments. The construction of the 46,000-square-foot facility in Denton, Texas is set to commence this year and is expected to be fully operational by 2028. The site will create job opportunities in bioengineering, advanced manufacturing, quality control, and operations, contributing to the local economy and supporting Novartis' commitment to innovation in cancer therapy.
The addition of the Texas plant will strengthen Novartis' network of radioligand therapy sites across the U.S., which includes facilities in New Jersey, Indiana, and California, as well as a recently announced site in Florida. By expanding its manufacturing footprint, Novartis aims to enhance its ability to deliver cutting-edge treatments with speed and precision, ensuring that patients have access to innovative therapies for cancer and other diseases. The company's investment in domestic manufacturing reflects its commitment to advancing healthcare and meeting the evolving needs of patients worldwide.